Congruence Therapeutics
Edith Bellavance is an accomplished professional in drug metabolism and pharmacokinetics (DMPK) with extensive experience spanning nearly two decades. Currently serving as Directrice exécutive at Congruence Therapeutics since April 2023, Bellavance previously held various roles at Paraza Pharma Inc from April 2013, including Director, Associate Director, Manager, and Scientist in DMPK. Prior to this, Bellavance gained valuable experience as a Research Associate at Boehringer Ingelheim and as a Scientist at Charles River Laboratories. Edith Bellavance holds a Master of Science in Molecular Endocrinology from Université Laval and a Bachelor of Science in Biochemistry from Université de Sherbrooke.
This person is not in any teams
Congruence Therapeutics
Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.